Revenue Performance - Revenue for 2025 totaled $16,548,734, an increase of 3.2% from $16,039,513 in 2024[7] - Import revenue rose by 36.0% to $4,837,876, with import loads increasing by 54.7% to 6,275[10] - Scrap metal revenue increased by 77.4% to $2,041,790, while waste metal loads grew by 94.1% to 2,413[10] - Waste paper revenue declined by 14.5% to $9,153,668, reflecting a soft market[12] Profitability and Expenses - Gross profit decreased to $497,725 in 2025, down 71.9% from $1,768,600 in 2024, resulting in a gross margin of 3.0%[8] - Selling, general and administrative expenses surged by 226.2% to $7,875,263, primarily due to public company costs and personnel expansion[9] - Net loss for 2025 was $(7,344,586), compared to net income of $174,871 in 2024[9] Financial Position - Cash increased to $1,202,395 at year-end, total assets rose to $10,995,741, and shareholders' equity increased to $8,621,558[10] Operational Expansion - The company expanded its operations in Ensenada, Mexico, and Texas, enhancing its logistics capabilities[4] - Total loads completed decreased by 1.0% to 22,443, with notable growth in waste metal and import loads[14]

Financial Performance - In 2025, Cyngn's revenue was $219 thousand, a decrease from $368 thousand in 2024[11] - Total costs and expenses in 2025 were $25.9 million, an increase of 11.6% from $23.2 million in 2024[12] - The net loss for 2025 was $(23.5) million, compared to $(33.3) million in 2024, resulting in a net loss per share of $(5.17) based on approximately 4.5 million shares outstanding[13] - In Q4 2025, revenue was $68.1 thousand, down from $306.4 thousand in Q4 2024[14] - Total costs and expenses in Q4 2025 were $6.6 million, an increase of 17% from $5.6 million in Q4 2024[15] - The net loss for Q4 2025 was $(5.7) million, compared to $(16.1) million in Q4 2024, with a net loss per share of $(0.78) based on approximately 7.2 million shares outstanding[16] - Net loss for the year ended December 31, 2024, was $23,469,273, compared to a net loss of $33,335,579 in 2025, indicating an improvement of approximately 29%[25] Cash and Investments - Cyngn's unrestricted cash and short-term investments as of December 31, 2025, totaled $34.7 million, up from $23.6 million as of December 31, 2024[17] - Total stockholders' equity as of December 31, 2025, was $38.8 million, compared to $(1) million as of December 31, 2024[17] - Cash used in operating activities for 2024 was $23,576,656, an increase from $19,196,081 in 2025, reflecting a higher cash burn rate[25] - Cash provided by financing activities in 2024 was $35,083,353, slightly down from $36,286,961 in 2025, showing a stable financing environment[25] - The company reported a significant increase in cash and cash equivalents, ending 2024 with $990,023 compared to $23,617,733 at the beginning of the year[25] Business Development - Cyngn reported a record expansion among enterprise and Fortune 100 customers, with Q1 2026 sales expected to exceed total 2025 bookings[6] - The company closed a $9.65 million registered direct offering, extending its runway until 2028[9] - Cyngn plans to continue expanding its product offerings and market presence in the autonomous vehicle sector, leveraging its innovative technology[29] Product and Technology - Cyngn's DriveMod technology is currently available on Motrec MT-160 Tuggers and BYD Forklifts, targeting industrial organizations facing labor shortages[27] - DriveMod Tugger can haul up to 12,000 lbs and aims for a typical payback period of less than 2 years, enhancing operational efficiency for customers[27] - The company is focused on addressing challenges in industrial organizations, such as costly safety incidents and labor shortages, through its autonomous vehicle technology[26] Financial Adjustments and Risks - The company has made adjustments to its financial statements to reflect a 1-for-100 reverse stock split and a 1-for-150 reverse stock split, impacting share structure[25] - Cyngn's management emphasizes the importance of forward-looking statements, highlighting potential risks and uncertainties that could affect future results[29]

Financial Performance - The company incurred operating losses of $6,249,000 and $1,302,000 for the years ended December 31, 2025, and December 31, 2024, respectively, with an accumulated deficit of approximately $8.4 million as of December 31, 2025[60]. - As of December 31, 2025, the company had cash and cash equivalents of $1.3 million and bank deposits of $16.2 million, indicating a need for substantial additional funding[68]. - The company has never generated revenue from product candidate sales and does not expect to do so for at least the next year[63]. Regulatory and Approval Challenges - The company is subject to risks related to the discovery, development, and clinical testing of product candidates, which may impact the timeline for achieving marketing approvals[75]. - The FDA's 510(k) clearance process typically takes 3 to 12 months, while the PMA process can take 1 to 3 years or longer, with significant costs involved[79]. - The company has not yet conducted a pre-submission meeting with the FDA's CDRH for its PL-16 product candidate, which may lead to a lengthier approval process if a different pathway is required[86]. - Compliance with the EU Medical Devices Regulation is necessary for the company to market its products in the EU, requiring a conformity assessment procedure[84]. - Legislative or regulatory reforms in the US or EU may increase the difficulty and costs associated with obtaining regulatory clearances or approvals[87]. - The company may face delays or limitations in regulatory approvals due to the need for extensive data to demonstrate safety and effectiveness[78]. - The company must demonstrate that its devices meet the General Safety and Performance Requirements to obtain the CE mark for marketing in the EU[84]. - Regulatory approval processes for the FDA and EMA are lengthy and unpredictable, with no assurance of obtaining approval for current or future product candidates[100]. - The company has not yet obtained regulatory approval to market any product in the United States or other jurisdictions, which could limit market opportunities[99]. - The company may need to conduct additional clinical trials or face delays due to unforeseen events during the clinical trial process[107]. Clinical Trials and Development Risks - The company may face difficulties in patient enrollment for clinical trials due to various factors, including eligibility criteria and competition from other trials[76]. - Clinical trials are expensive and can take many years to complete, with outcomes being inherently uncertain, potentially leading to significant delays[106]. - The company is in the early stages of pre-clinical development for its T&T platform, facing regulatory risks that may impact business and operational results[77]. - The company expects to incur significant incremental costs associated with the commercialization of product candidates, which may affect profitability[66]. - The company must establish a sales, marketing, and distribution infrastructure to commercialize any product candidates that receive marketing approval[64]. Competition and Market Dynamics - The company faces intense competition from both domestic and international pharmaceutical firms, which may develop more effective or cost-efficient products[151]. - The commercial success of the company's product candidates will depend on their acceptance by the medical community, including physicians and healthcare payors, which may require significant resources for education and outreach[230]. - The company anticipates pricing pressures on its product candidates due to managed healthcare trends and legislative changes, leading to intense downward pressure on healthcare costs[239]. Intellectual Property and Legal Risks - The company has a growing portfolio of patent applications, but uncertainties exist regarding the issuance and enforceability of these patents, which could affect commercialization[178]. - The company may face challenges in maintaining effective patent rights, which could adversely affect its ability to compete in the market[180]. - Third-party claims of intellectual property infringement may delay development and commercialization efforts, leading to substantial litigation expenses[191]. - Legal proceedings to protect intellectual property could be costly and time-consuming, with unpredictable outcomes that may impact the company's ability to raise funds for clinical trials and research programs[198]. Compliance and Regulatory Environment - The company is subject to various healthcare fraud and abuse laws, which could result in substantial penalties if not complied with[137]. - The company may face challenges in maintaining compliance with evolving healthcare laws and regulations, which could disrupt operations[143]. - Changes in FDA policies and government regulations could delay or prevent regulatory approval of product candidates, impacting profitability[132]. - The company is classified as a foreign private issuer, which allows it to follow home country corporate governance practices, potentially providing less protection to investors compared to U.S. domestic issuers[249]. Operational and Growth Challenges - The company may need to manage growth effectively to avoid operational disruptions, which could lead to increased expenses and reduced revenue generation capabilities[208]. - Limited resources may force the company to prioritize certain product candidates over others, potentially leading to missed opportunities and adverse effects on revenues[209]. - The company may struggle to identify, discover, or license additional product candidates, which is critical for its business success[210]. - Reliance on third-party vendors for clinical trials and data management poses risks, including potential delays and increased costs if these parties fail to meet obligations[162]. Economic and Market Conditions - Economic conditions, including inflation and liquidity risks, could adversely impact the company's business, operating results, and financial condition[221]. - The company may face increased costs and compliance obligations related to sustainability and ESG initiatives, which could negatively affect its financial performance[220].

Drug Development and Clinical Trials - The lead drug candidate, (Z)-endoxifen, is currently in Phase 2 clinical development, focusing on breast cancer treatment and prevention [26]. - In a Phase 2 trial, the 1 mg dose of (Z)-endoxifen showed a mean mammographic breast density (MBD) reduction of 17.3% (p<0.01), while the 2 mg dose showed a mean reduction of 23.5% (p<0.01) compared to a 0.27% change in the placebo group [37]. - The ongoing I-SPY 2 study demonstrated a median MRI functional tumor volume reduction of approximately 72% and a Ki-67 proliferation index decrease from an average of 16% to 10% [39][40]. - The RECAST study is evaluating (Z)-endoxifen for low-risk ductal carcinoma in situ (DCIS), with early findings suggesting feasibility and tolerability [43][44]. - The EVANGELINE study is assessing (Z)-endoxifen plus ovarian function suppression (OFS) in premenopausal women, with early data showing approximately 86% of patients achieving a Ki-67 value of 10% or less at Week 4 [47]. - The company has received FDA designations for (Z)-endoxifen for DMD, including Rare Pediatric Disease Designation and Orphan Drug Designation, which may provide strategic benefits [51]. - The company is exploring (Z)-endoxifen's application in rare diseases, including McCune-Albright Syndrome, with plans to seek FDA designations in 2026 [53]. - The company has received Rare Pediatric Disease designation from the FDA for (Z)-Endoxifen for Duchenne Muscular Dystrophy, but this does not guarantee faster development or regulatory review [193]. - The regulatory pathway for product candidates is complex, requiring significant research, development, and clinical investigation before marketing approval can be obtained [190]. Market Potential and Financial Overview - The global ER+ breast cancer treatment market is projected to reach approximately $30 billion by 2030, growing at a CAGR of about 7% [54]. - The potential U.S. market for (Z)-endoxifen in breast cancer treatment and prevention could be up to $1 billion or more annually [54]. - Duchenne muscular dystrophy (DMD) affects over 200,000 boys globally, with an estimated therapeutics market of approximately $3 billion in 2025, projected to grow to $10 billion by 2030 [55]. - As of December 31, 2025, the company had cash and cash equivalents of approximately $41.3 million [61]. - The company reported net losses of $34.8 million and $25.5 million for the years ended December 31, 2025 and 2024, respectively [166]. - The company has a limited operating history and has incurred net losses each year since December 2015 [166]. - The company expects to continue incurring losses due to ongoing costs for the development of its programs, including clinical studies [166]. - The company may need to raise substantial additional capital in the future to fund its operations [161]. - The company anticipates needing to raise additional capital in the future to continue operations, as it currently has no ongoing sources of revenue [171]. - The company plans to obtain additional capital through equity securities sales and short-term borrowing, but there is no assurance of success in these efforts [171]. - Macroeconomic factors, including high interest rates and inflation, could adversely impact the company's ability to raise capital [168]. Regulatory Compliance and Risks - The FDA review user fee for submitting a New Drug Application (NDA) is $4.682 million for fiscal year 2026 [86]. - The Pediatric Research Equity Act (PREA) mandates pediatric clinical trials for most drugs, requiring a pediatric assessment in NDAs unless a deferral or waiver is granted [87]. - The FDA has various programs, including breakthrough therapy designation and accelerated approval, aimed at expediting drug review processes for serious conditions [90]. - The FDA requires post-marketing studies for drugs approved under accelerated approval to verify clinical benefits [90]. - The FDA may require inspections of clinical sites and manufacturing facilities before approving an NDA to ensure compliance and patient safety [91]. - The company is subject to various healthcare-related laws, including the federal Anti-Kickback Statute and the False Claims Act, which impose significant compliance obligations [150]. - Violations of the Anti-Kickback Statute can result in criminal fines, imprisonment, and exclusion from federal healthcare programs [149]. - Non-compliance with U.S. regulations may lead to severe sanctions, including product recalls and clinical holds [109]. - The company is subject to extensive regulation by the FDA and comparable agencies, which can delay or deny product approvals for various reasons [189][191]. - Any failure to comply with regulatory requirements by the company or its third-party service providers could lead to significant operational and financial consequences [206]. Intellectual Property and Competition - The company has 24 issued patents and is pursuing 141 pending patent applications related to its therapies, with expiration dates ranging from 2030 to 2047 [71]. - The company owns and is pursuing 141 pending patent applications and has 24 issued patents, which are crucial for protecting its proprietary technology and maintaining competitive advantage [222]. - The company faces significant competition from other biotechnology and pharmaceutical companies, which may impact its market position [165]. - The company may face uncertainties in the patent landscape, which may complicate the ability to obtain patent protection for its products [225]. Operational Challenges - The company relies on third-party contractors for manufacturing and clinical studies, which is integral to its operational strategy [75]. - The company is dependent on third-party service providers for critical operational activities, which could affect its business [161]. - The company relies heavily on third-party service providers for manufacturing and testing, which poses risks if these parties fail to meet their obligations [199]. - There is a risk of delays in clinical trials due to factors such as patient enrollment rates and regulatory approvals, which could impact commercialization [208]. - The company may experience difficulties in attracting and retaining qualified personnel, which could adversely affect its development activities [182]. - The company may face challenges in establishing commercial sales and marketing capabilities if its product candidates are approved [178]. - The company may face increased development costs and risks if clinical trials take longer than expected or yield different results than anticipated [186]. Financial Liabilities and Insurance - The company has recorded an estimated accrued current liability of $1.1 million and $1.5 million in its Consolidated Balance Sheets as of December 31, 2025, and December 31, 2024, respectively, due to changes in tax estimates related to R&D activities in Australia [220]. - The company maintains various insurance policies, including director's and officer's insurance and product errors and omissions liability insurance [156]. - The company maintains cash at financial institutions that often exceed federally-insured limits, posing a risk of loss in the event of bank failures [214]. Data Privacy and Security - The GDPR imposes fines for noncompliance of up to 4% of total worldwide annual turnover or €20 million, emphasizing strict data protection compliance [139]. - The California Consumer Privacy Act (CCPA) imposes additional obligations on businesses regarding personal information, further complicating compliance efforts [144]. - Non-compliance with privacy and security regulations can lead to significant civil and criminal penalties, loss of business, and negative publicity [147]. - The company is dependent on the performance of third-party vendors for information technology systems, which could expose it to cybersecurity risks [205].

IPO and Financing - The company completed its Initial Public Offering (IPO) on June 20, 2024, raising gross proceeds of $230,000,000 from the sale of 23,000,000 Units at $10.00 per Unit[21]. - An additional $6,000,000 was generated from the private sale of 6,000,000 Private Placement Warrants at $1.00 each[22]. - A total of $230,000,000, including $224,000,000 from the IPO and $6,000,000 from the Private Placement, has been placed in a Trust Account[23]. - The company has approximately $246,161,982 available for a Business Combination as of December 31, 2025, before accounting for a $9,800,000 Deferred Fee and any applicable taxes[54]. - The company intends to complete its initial Business Combination using cash from its Initial Public Offering and Private Placement, as well as potential debt or equity securities[55]. - The company may seek additional financing if the cash portion of the purchase price exceeds the amount available from the Trust Account, net of redemptions by Public Shareholders[57]. - The company may raise funds through equity-linked securities or loans to satisfy cash requirements for the initial Business Combination[84]. - The company completed the sale of 6,000,000 Private Placement Warrants at a purchase price of $1.00 per warrant, generating gross proceeds of $6,000,000[151]. - A total of $230,000,000 from the net proceeds of the Initial Public Offering and Private Placement was placed in the Trust Account[152]. Business Combination Strategy - The company seeks to acquire established businesses with proven unit economics and capable management teams, avoiding startups or companies without established plans[33]. - The Management Team has developed a broad network of contacts that provides a substantial number of potential Business Combination targets[41]. - The company may pursue Business Combinations with affiliated companies, provided an independent valuation opinion is obtained to ensure fairness[44]. - The Management Team's investment philosophy emphasizes unlocking value and growth potential for investors and target businesses[29]. - The company offers target businesses a more expeditious and cost-effective method to go public compared to traditional initial public offerings[51]. - The company may engage professional firms to assist in identifying Business Combination opportunities, potentially incurring finder's fees or consulting fees[48]. - The company may continue to seek a Business Combination with a different target if the initial one is not completed within the Combination Period[92]. Redemption and Shareholder Rights - Public Shareholders can redeem their shares regardless of their voting decision on the initial Business Combination[74]. - If shareholder approval is sought, at least 7,666,667 Public Shares (33.3% of 23,000,000) must be voted in favor for the initial Business Combination to be approved[79]. - Public Shareholders are restricted from redeeming more than 15% of the Ordinary Shares sold in the Initial Public Offering without prior consent[86]. - The company may conduct redemptions without a shareholder vote under certain conditions, but will seek shareholder approval if required by law or stock exchange rules[63]. - Public Shareholders must deliver their share certificates or Public Shares electronically to exercise redemption rights, with a deadline of up to two business days before the scheduled vote on the initial Business Combination[88]. - A fee of approximately $100.00 may be charged by the transfer agent for the delivery of Public Shares, which may be passed on to the redeeming holder at the broker's discretion[89]. - If the initial Business Combination is not approved, Public Shareholders who elected to redeem their shares will not receive a pro rata share of the Trust Account[91]. - The redemption price for Public Shares upon liquidation is expected to be approximately $10.70 as of December 31, 2025, before taxes and less up to $100,000 for dissolution expenses[97]. - The Trust Account may be subject to claims from creditors, which could reduce the actual redemption amount below $10.00 per Public Share[99]. - Public Shareholders are entitled to funds from the Trust Account only under specific conditions, including failure to complete the initial Business Combination within the Combination Period[103]. Risks and Challenges - The company may face conflicts of interest as its officers and directors may pursue other SPACs or business ventures during the search for a Business Combination[47]. - The company may depend on the future performance of a single business post-Business Combination, which could limit diversification and increase risk[58]. - The company may not have the ability to retain key personnel from the target business after the Business Combination, which could impact management effectiveness[60]. - The company is facing competition from other entities, including SPACs and private equity groups, which may limit its ability to acquire larger target businesses due to available financial resources[104]. - The company may face challenges in obtaining additional financing for the initial Business Combination, which could impact its operations and growth[116]. - The ability of Public Shareholders to redeem their shares for cash may make the company less attractive to potential Business Combination targets[117]. - The company may face challenges in completing its initial Business Combination due to limited resources and significant competition[118]. - If the initial Business Combination is not completed by June 20, 2026, Public Shareholders may have to wait longer for redemption[118]. - The company may face regulatory review and approval requirements that could hinder the completion of its initial Business Combination[122]. - Key personnel from the target business may resign after the Business Combination, negatively impacting operations and profitability[122]. - The company may be subject to changing laws and regulations that increase costs and risks of non-compliance[122]. Financial Performance - The company reported a net income of $8,952,273 for the year ended December 31, 2025, primarily from interest income on marketable securities held in the Trust Account[156]. - For the period from February 21, 2024, to December 31, 2024, the company had a net income of $5,839,656, also from interest income on marketable securities[157]. - As of December 31, 2025, the company had marketable securities in the Trust Account valued at $246,161,982, including $16,161,982 of interest income[161]. - Cash used in operating activities for the year ended December 31, 2025, was $585,477, with net income affected by interest earned on marketable securities[159]. - The company has not engaged in any operations or generated revenues to date, with activities focused on the Initial Public Offering and evaluating acquisition candidates[155]. Corporate Governance - The Board of Directors consists of five members divided into three classes, with each class serving a three-year term[215]. - The first class of directors, including Mr. Sheriff and Ms. Cohen, will have their term expire at the first annual general meeting[216]. - The Audit Committee is composed of independent members: Messrs. Hawkins and Meltzer, and Ms. Cohen[219]. - There are no family relationships among the directors or executive officers[211]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements until it meets specific revenue or market value thresholds[110]. - The company will remain a smaller reporting company until it meets certain market value or revenue criteria, allowing for reduced disclosure obligations[113]. - The company is considered a "controlled company" under Nasdaq standards, which may exempt it from certain corporate governance requirements[114]. - The company is not required to hold an annual general meeting until one year after its first fiscal year end following its Nasdaq listing[216]. Legal and Compliance - The company is incorporated in the Cayman Islands, which may limit shareholders' ability to protect their rights through U.S. Federal courts[126]. - The company has not encountered any cybersecurity incidents since its IPO, but it remains vulnerable to such risks[132]. - The company incurred legal fees of $50,000 paid on June 25, 2024, related to Wasserstrom[176]. - Legal fees incurred from Wasserstrom amounted to $125,000 for both 2025 and 2024, with a remaining balance of deferred legal fees of $200,000 as of December 31, 2025[176]. - The company is subject to various risks that could impact its ability to complete an initial Business Combination, including geopolitical instability and economic downturns[129]. - The company may amend certain agreements related to the IPO without shareholder approval, which could adversely affect the value of investments in its securities[128].

IPO and Financing - The company completed its Initial Public Offering (IPO) on June 20, 2024, raising gross proceeds of $230,000,000 from the sale of 23,000,000 Units at $10.00 per Unit[21]. - An additional $6,000,000 was generated from the private sale of 6,000,000 Private Placement Warrants at $1.00 each, bringing total gross proceeds to $236,000,000[22]. - The total amount of $230,000,000 from the IPO and Private Placement has been placed in a Trust Account[23]. - The company has approximately $246,161,982 available for a Business Combination as of December 31, 2025, before accounting for a $9,800,000 Deferred Fee and any applicable taxes[54]. - The company intends to complete its initial Business Combination using cash from its Initial Public Offering and Private Placement, as well as potential debt or equity securities[55]. - The company may seek additional financing if the cash portion of the purchase price exceeds the amount available from the Trust Account, net of redemptions by Public Shareholders[57]. - The company may raise funds through equity-linked securities or loans to satisfy cash requirements for the initial Business Combination[84]. - The company has approximately $230,540 in proceeds held outside the Trust Account as of December 31, 2025, to cover costs associated with liquidation and creditor claims[96]. Business Combination Requirements - The company must complete its initial Business Combination by June 20, 2026, or face termination and distribution of Trust Account funds[24]. - The Nasdaq Rules require that the Business Combination must have an aggregate fair market value of at least 80% of the Trust Account assets[38]. - The company seeks to acquire established businesses with proven unit economics and capable management teams, avoiding startups or companies without established plans[33]. - The company may pursue an initial Business Combination with affiliated companies, provided an independent valuation opinion is obtained[44]. - Shareholder approval may be required for the initial Business Combination under Nasdaq Rules, depending on specific circumstances[64]. - The company requires 7,666,667, or 33.3%, of the 23,000,000 Public Shares sold in the Initial Public Offering to be voted in favor of the initial Business Combination for approval[79]. - The company may consider extending the Combination Period with shareholder approval, which could affect its Nasdaq listing[25]. Redemption and Shareholder Rights - Public Shareholders are restricted from redeeming more than 15% of the Ordinary Shares sold in the Initial Public Offering without prior consent, to prevent accumulation of large blocks of shares[86]. - If the aggregate cash consideration for redemptions exceeds available cash, the company will not complete the initial Business Combination[73]. - The company will not restrict Public Shareholders' ability to vote all of their Public Shares for or against the initial Business Combination[87]. - Public Shareholders can only receive funds from the Trust Account under specific conditions, including failure to complete the initial Business Combination within the Combination Period[103]. - If the initial Business Combination is not approved, Public Shareholders who elected to redeem their shares will not be entitled to redeem for their pro rata share of the Trust Account[91]. - The company intends to require Public Shareholders to deliver their shares to the transfer agent prior to the redemption date to facilitate efficient processing[83]. - The company intends to require Public Shareholders to deliver their share certificates or Public Shares electronically to exercise redemption rights, with a deadline of up to two business days prior to the scheduled vote on the initial Business Combination[88]. - A nominal fee of approximately $100.00 will be charged by the transfer agent for the delivery of Public Shares, which may be passed on to the redeeming holder at the broker's discretion[89]. Financial Performance and Risks - The company reported a net income of $8,952,273 for the year ended December 31, 2025, primarily from interest income on marketable securities held in the Trust Account[156]. - For the period from February 21, 2024, through December 31, 2024, the company had a net income of $5,839,656, also from interest income on marketable securities[157]. - The company incurred fees of $14,462,875 related to the Initial Public Offering, including a cash underwriting fee of $4,000,000[158]. - Cash used in operating activities for the year ended December 31, 2025, was $585,477, with net income affected by interest earned on marketable securities[159]. - The company may face significant dilution for Public Shareholders due to the nominal purchase price of Founder Shares by the Sponsor, which was $25,000 or approximately $0.003 per share[126]. - The company is subject to various risks that could adversely affect its ability to complete an initial Business Combination, including geopolitical instability and economic downturns[129]. - The company may face challenges in completing its initial Business Combination due to limited resources and significant competition[118]. - The ability of public shareholders to redeem their shares for cash may impact the company's financial condition and attractiveness to potential Business Combination targets[117]. Management and Governance - The company has three officers who are not obligated to devote specific hours until the initial Business Combination is completed[105]. - The Board of Directors consists of five members, divided into three classes, with each class serving a three-year term[215]. - The Audit Committee is composed of independent members: Messrs. Hawkins and Meltzer, and Ms. Cohen[219]. - The company has established two standing committees: the Audit Committee and the Compensation Committee[218]. - The company is currently involved in a putative class action lawsuit alleging fiduciary-duty breaches and unjust enrichment[213]. - Mr. Meltzer is also named in consolidated derivative lawsuits related to his previous role at Hain Celestial Group[214]. Regulatory and Compliance - The company is required to evaluate its internal control procedures for the fiscal year ending December 31, 2025, as mandated by the Sarbanes-Oxley Act[108]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[110]. - The company will remain an emerging growth company until it meets specific revenue or market value thresholds, including total annual gross revenue of at least $1.235 billion[112]. - The company is also classified as a "smaller reporting company," which allows it to provide only two years of audited financial statements[113]. - The company may face regulatory challenges that could delay or prevent the completion of its initial Business Combination[122]. - The company has maintained effective disclosure controls and procedures as of December 31, 2025[183]. Target Business Strategy - The company is focusing its search for target businesses on established companies poised for growth, led by reputable management teams[149]. - The Management Team has developed a broad network of contacts that provides a substantial number of potential Business Combination targets[41]. - The company may engage finders to identify Business Combination opportunities, with fees typically tied to the completion of a transaction[50]. - The company may depend entirely on the future performance of a single business after its initial Business Combination, limiting diversification[58]. - The company may not have the ability to evaluate the target's management team accurately, which could impact future performance[59]. - Key personnel from the target business may resign after the Business Combination, negatively impacting operations and profitability[122].

IPO and Financing - The company completed its Initial Public Offering (IPO) on June 20, 2025, raising gross proceeds of $200 million from the sale of 20 million Public Units at $10.00 each[19]. - A private sale of 600,000 Private Placement Units was completed simultaneously with the IPO, generating an additional $6 million in gross proceeds[20]. - The total amount of $200 million from the IPO and Private Placement has been placed in a Trust Account[21]. - The total funds available for a Business Combination amount to $204,234,694, before payment of $8,000,000 in Deferred Fees and excluding $736,280 held outside of the Trust Account for working capital[60]. - The company may need to obtain additional financing to complete the initial Business Combination, which could lead to significant dilution for Public Shareholders[61]. - The company may raise funds through equity-linked securities or loans to meet cash requirements for the initial Business Combination[101]. - The company has approximately $736,280 in proceeds held outside the Trust Account as of December 31, 2025, to cover costs associated with potential liquidation[113]. - The company has a liability to ensure that the Trust Account does not fall below $10.00 per Public Share due to claims by third parties[117]. Business Combination Requirements - The company must complete its initial Business Combination by June 20, 2027, or face termination and distribution of Trust Account amounts[22]. - If the initial Business Combination is not completed by June 20, 2027, the company will redeem 100% of the Public Shares at a pro rata price of approximately $10.00 per share[54]. - The company anticipates structuring the initial Business Combination so that the post-transaction entity will own or acquire at least 50% of the target business[56]. - The company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account[55]. - The company will redeem Public Shares at a per-share price equal to the aggregate amount in the Trust Account if the initial Business Combination is not completed within the Combination Period[110]. - If the company does not complete its initial Business Combination within the Combination Period, it will liquidate and redeem its Public Shares[135]. Shareholder Considerations - Public Shareholders incurred immediate and material dilution upon the closing of the Initial Public Offering due to the nominal price of $0.004 per share for Founder Shares[45]. - The anti-dilution provisions of the Founder Shares may result in the issuance of Class A Ordinary Shares on a greater than one-for-one basis upon conversion, leading to further dilution for Public Shareholders[47]. - The company may issue Class A Ordinary Shares upon conversion of Class B Ordinary Shares at a ratio greater than one-to-one, further impacting Public Shareholders[48]. - Public Shareholders can redeem their shares either through a general meeting or a tender offer, at the company's discretion[90]. - A minimum of 6,566,667 Public Shares, or approximately 32.38% of the 20,000,000 Public Shares sold, is needed for an Ordinary Resolution to approve the initial Business Combination[95]. - If a Special Resolution is required, 11,111,112 Public Shares, or approximately 55.56%, must be voted in favor of the Business Combination[95]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[103]. - The company intends to require Public Shareholders to deliver their share certificates or electronically transfer their shares to exercise redemption rights[100]. Market Opportunities - The European energy market is projected to reach $92.5 billion by 2030, with a CAGR of 3.6% driven by renewable energy sources[32]. - The European data center market size reached $54.5 billion in 2023 and is expected to grow to $118.2 billion by 2032, with a CAGR of 8.9%[33]. - The European airline industry market was valued at $45.0 billion in 2023 and is projected to reach $70.1 billion by 2032, with an expected CAGR of 6.7%[36]. - The European freight and logistics market size was valued at $2.4 trillion in 2023 and is projected to reach $3.8 trillion by 2031, growing at a CAGR of 5.4%[38]. - The European edge computing market size is expected to reach $50.8 billion by 2032, driven by the adoption of IoT devices and demand for low-latency solutions[35]. Management and Governance - The company has a diverse board of directors with significant experience in various industries, including technology and finance[210]. - Richard H. Dodd has served as Executive Chairman since inception and has extensive experience in M&A and technology sectors[211]. - Douglas Ward has been the CEO since inception, with a background in telecommunications and technology[213]. - W. Robert Dilling, Jr. has been the CFO since inception, bringing experience from various financial leadership roles[214]. - Christoph Ackermann has served as COO since inception, with a strong background in operational management and consulting[215]. - Dr. Claire Handby and Steven Leighton joined the board in June 2025, bringing expertise in business growth and telecommunications respectively[216][217]. Risks and Challenges - The company may face challenges in completing its initial Business Combination due to competition for attractive targets and potential financing difficulties[133]. - The company may face significant dilution of public shareholders' investments due to the nominal purchase price of Founder Shares compared to their potential value post-Business Combination[144]. - The company may face a lack of business diversification, as success may depend entirely on the performance of a single business post-initial Business Combination[74]. - There is no assurance that key personnel will remain in senior management positions after the Business Combination, which could impact the management of the combined company[76]. - The company may face conflicts of interest if its officers and directors pursue other SPACs or business ventures during the search for an initial Business Combination[68]. - The company may be subject to regulatory review and approval requirements that could hinder the completion of its initial Business Combination[141]. - Geopolitical conditions, such as the Russia-Ukraine conflict and tensions in the Middle East, may adversely affect the company's ability to find a target business[146]. Financial Performance - As of December 31, 2025, the company had net income of $3,649,620, primarily from interest earned on investments held in the Trust Account of $4,234,694, offset by general and administrative expenses of $585,074[179]. - The total amount placed in the Trust Account after the Initial Public Offering was $200,000,000, with fees incurred totaling $12,624,206, including a cash underwriting fee of $4,000,000[180]. - Cash used in operating activities for the period was $260,978, with net income impacted by interest earned and general administrative expenses paid through various means[181]. - As of December 31, 2025, the company held marketable securities in the Trust Account amounting to $204,234,694, which includes approximately $4,234,964 of interest income[182]. - The company had cash held outside the Trust Account of approximately $736,280 and working capital of $766,937, primarily used for identifying and evaluating target businesses[184]. - The company does not have any long-term debt or capital lease obligations, with administrative service fees incurred totaling $58,300 from June 17, 2025, to December 31, 2025[189]. Compliance and Reporting - The company is classified as an "emerging growth company" and can delay the adoption of certain accounting standards until they apply to private companies[128]. - The company will remain an emerging growth company until it has total annual gross revenue of at least $1.235 billion or the market value of its Class A Ordinary Shares exceeds $700 million[130]. - The company is also a "smaller reporting company," allowing it to provide only two years of audited financial statements until certain revenue and market value thresholds are met[131]. - The management report on internal control over financial reporting is not included due to a transition period established by SEC rules for newly public companies[204]. - No changes in internal control over financial reporting were reported[205].

IPO and Financing - The company completed its Initial Public Offering (IPO) on June 20, 2025, raising gross proceeds of $200 million from the sale of 20 million Public Units at $10.00 each[19]. - A private sale of 600,000 Private Placement Units was completed simultaneously with the IPO, generating an additional $6 million in gross proceeds[20]. - The total amount of $200 million from the IPO and Private Placement has been placed in a Trust Account[21]. - The company has $204,234,694 available for a Business Combination, excluding $8,000,000 in Deferred Fees and $736,280 held for working capital[60]. - The company incurred total fees of $12,624,206 related to the Initial Public Offering, including a cash underwriting fee of $4,000,000 and a Deferred Fee of $8,000,000[180]. - The Sponsor contributed $25,000 for the issuance of Founder Shares and provided a loan of up to $300,000 under the IPO Promissory Note, which was fully repaid[185][186]. - The Underwriters of the Initial Public Offering partially exercised their Over-Allotment Option, purchasing 2,500,000 Option Units[190]. - The company does not expect to raise additional funds for operating expenditures but may need additional financing to complete the Business Combination if necessary[188]. Business Combination Requirements - The company must complete its initial Business Combination by June 20, 2027, or face termination and distribution of Trust Account amounts[22]. - The company has until June 20, 2027, to consummate its initial Business Combination, with the option to seek shareholder approval for an extension[53]. - If the initial Business Combination is not completed within the Combination Period, the company will redeem 100% of Public Shares at approximately $10.00 per share[54]. - The company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account[55]. - The company may not complete the initial Business Combination if the cash consideration required exceeds the available cash[89]. - The company may only complete one Business Combination with the proceeds from its Initial Public Offering, leading to a lack of diversification that could negatively impact operations and profitability[137]. - The company may attempt to complete multiple Business Combinations simultaneously, which could increase costs and risks[133]. Shareholder Rights and Redemption - Public Shareholders can redeem their shares either through a general meeting or a tender offer, with the decision made at the company's discretion[90]. - A quorum for shareholder meetings requires at least one-third of issued and outstanding Ordinary Shares to be represented[94]. - To approve an Ordinary Resolution for the initial Business Combination, approximately 32.38% of the 20,000,000 Public Shares sold in the Initial Public Offering must be voted in favor[95]. - If a Special Resolution is required, approximately 55.56% of the Public Shares must be voted in favor for approval[95]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[103]. - The company intends to require Public Shareholders to deliver their share certificates or electronically transfer their shares to exercise redemption rights[100]. - A nominal fee of approximately $100.00 may be charged by the transfer agent for processing redemptions[106]. - Funds for redeeming Public Shares will be distributed promptly after the completion of the initial Business Combination[107]. Market Opportunities and Industry Insights - The European infrastructure investment gap could reach $2 trillion by 2040, highlighting significant opportunities in the market[26]. - The European airline industry market was valued at $45 billion in 2023 and is projected to reach $70.1 billion by 2032, with a CAGR of 6.7%[36]. - The European freight and logistics market size was valued at $2.4 trillion in 2023 and is projected to reach $3.8 trillion by 2031, growing at a CAGR of 5.4%[38]. - The European data center market size reached $54.5 billion in 2023 and is projected to grow to $118.2 billion by 2032, with a CAGR of 8.9%[33]. - The European edge computing market size is expected to reach $50.8 billion by 2032, driven by the adoption of IoT devices and demand for low-latency solutions[35]. - The integration of AI in telecommunications could unlock $200 to $280 billion in value through improved customer service and network operations[40]. - The company is focusing its search for target businesses in the European infrastructure industry, indicating a strategic direction for future acquisitions[172]. Management and Governance - The company has a diverse board of directors with significant experience in various industries, including technology, finance, and operations[210]. - Richard H. Dodd has served as Executive Chairman since inception and has extensive experience in M&A and technology sectors[211]. - Douglas Ward, the CEO, has a background in telecommunications and technology, having co-founded multiple companies[213]. - W. Robert Dilling, the CFO, has a strong financial leadership background across diverse industries, including cloud-based software[214]. - Christoph Ackermann, the COO, has experience in transformation consulting and has worked with various companies in the financial sector[215]. - Dr. Claire Handby, an independent director, has over 15 years of experience in major infrastructure investment and financial advisory[216]. - Steven Leighton, an independent director, has significant experience in telecommunications and energy distribution, having served as CEO of multiple companies[217]. Risks and Challenges - The company may face challenges in completing its initial Business Combination due to competition for attractive targets and potential financing difficulties[133]. - The company may face significant write-downs or charges post-Business Combination, adversely affecting financial condition and shareholder value[141]. - The management team may not maintain control of the target business after the Business Combination, which could impact operations and profitability[141]. - The company may be subject to regulatory review and approval requirements that could hinder the completion of its initial Business Combination[141]. - Geopolitical conditions and armed conflicts, such as the Russia-Ukraine conflict, may adversely affect the company's ability to find a target business[146]. - The company may face significant economic volatility due to disruptions in the flow of oil and related commodities resulting from geopolitical tensions[146]. - The company may face risks related to inflation and interest rate fluctuations, which could impact its ability to consummate an initial Business Combination[134]. - The company may seek Business Combination opportunities in industries outside of its management's expertise, which could pose risks to shareholders[137]. - There is no requirement for an independent valuation opinion for the target business, potentially leaving shareholders without assurance of a fair price[137]. - The company may encounter competition from other SPACs, private equity groups, and public companies, which may limit its ability to acquire larger target businesses[122]. Financial Performance - As of December 31, 2025, the company had net income of $3,649,620, primarily from interest earned on investments held in the Trust Account of $4,234,694, offset by general and administrative expenses of $585,074[179]. - Total cash held in the Trust Account was $204,234,694, including approximately $4,234,964 of interest income, which will be used to complete the Business Combination[182]. - Cash used in operating activities for the period was $260,978, with net income impacted by general and administrative expenses paid through advances from the Sponsor totaling $140,242[181]. - The company had cash held outside the Trust Account of approximately $736,280 and working capital of $766,937 as of December 31, 2025[184]. - The company has not paid any cash dividends to date and does not plan to do so before completing a Business Combination[162]. Compliance and Reporting - The company is required to file annual, quarterly, and current reports with the SEC, ensuring transparency in its financial reporting[124]. - Audited financial statements of prospective target businesses will be provided to shareholders as part of proxy solicitation materials[125]. - The company is classified as an "emerging growth company" and is eligible for certain exemptions from reporting requirements, including not needing to comply with auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act[128]. - The company will remain an emerging growth company until it has total annual gross revenue of at least $1.235 billion or the market value of its Class A Ordinary Shares held by non-affiliates exceeds $700 million[130]. - The company is also a "smaller reporting company," allowing it to provide only two years of audited financial statements until certain market value or revenue thresholds are met[131]. - The management report on internal control over financial reporting is not included due to a transition period established by SEC rules for newly public companies[204]. - The company has not adopted or terminated any "Rule 10b5-1 trading arrangement" during the quarterly period ended December 31, 2025[206].

Financial Performance - Immix Biopharma, Inc. reported general and administrative expenses of $13,697,817 for the year ended December 31, 2025, an increase from $11,381,978 in 2024, primarily due to higher employee compensation and professional services costs [358][359]. - Research and development expenses rose to $16,258,598 in 2025 from $11,292,702 in 2024, driven by costs associated with ongoing clinical trials and increased spending funded by share offerings totaling net proceeds of $107,349,347 [360][361]. - Interest income decreased to $555,526 in 2025 from $1,017,354 in 2024, attributed to lower balances in money market funds [362]. - Net cash used in operating activities for the year ended December 31, 2025 was $23,930,304, primarily due to a net loss of $29,438,613 [379]. - Net cash provided by financing activities was $107,386,859 for the year ended December 31, 2025, primarily from the sale of common stock [381]. - Net cash used in investing activities was $7,213,785 for the year ended December 31, 2025, primarily for short-term investments [380]. - The company recorded stock-based compensation expense of $2,441,875 for the year ended December 31, 2025 [379]. Funding and Capital - The company received approximately $6.2 million in grant reimbursements from the California Institute for Regenerative Medicine (CIRM) as part of an $8 million grant awarded to support the clinical development of NXC-201 [367]. - Immix Biopharma conducted an underwritten public offering in December 2025, selling 19,117,646 shares at $5.10 per share, resulting in net proceeds of approximately $93.7 million after underwriting discounts [371]. - The company completed a private placement in September 2025, raising approximately $9.3 million from the sale of 3,915,604 shares and warrants [370]. - The company entered into an At The Market Offering Agreement in June 2025, allowing for the sale of up to $50 million in shares, with net proceeds of $4,409,430 from sales in 2025 [369]. - The company anticipates needing additional capital beyond the next 12 months to continue planned operations [373]. Operational Expenses - Immix Biopharma's primary cash usage is for operating expenses, including clinical research and development, with expectations of increased expenses as clinical programs expand [365]. - The company expects to incur significant commercialization expenses if marketing approval is obtained for any product candidates [372]. - The company has committed to funding NXC-201 clinical trials in Israel with an estimated total cost of approximately $13 million over four years [353]. - The company entered into a long-term operating lease agreement for biopharmaceutical manufacturing space with total lease payments expected to be $1.4 million through December 2033 [377]. - The company has no long-term manufacturing and supply agreements but enters into contracts on an as-needed basis [378]. Strategic Considerations - The company has incurred significant net losses since inception and does not expect to generate revenue until regulatory approval and commercialization of its product candidates [364]. - The company may need to relinquish valuable rights to technologies or revenue streams if additional funds are raised through collaborations or strategic alliances [374]. - As of December 31, 2025, the company had total assets of approximately $104.8 million and working capital of approximately $91.1 million [373].

Financial Performance - Consolidated net sales for Q2 FY2026 were $154.8 million, a 6% increase from $145.5 million in the prior year[5] - Net earnings for Q2 FY2026 were $16.3 million, or $0.31 per diluted share, compared to $20.9 million, or $0.38 per diluted share in the prior year[7] - Adjusted EBITDA for Q2 FY2026 was $33.0 million, with an adjusted EBITDA margin of 21.3%, down from 23.2% in the prior year[8] - Net sales for the three months ended February 28, 2026, were $154.807 million, an increase from $145.528 million in the same period of 2025, representing a growth of 8.8%[22] - Operating profit for the three months ended February 28, 2026, was $25.020 million, compared to $30.820 million in the same period of 2025, a decline of 18.8%[22] - Net earnings for the six months ended February 28, 2026, were $35.439 million, down from $42.624 million in 2025, a decrease of 16.7%[22] - Adjusted net earnings for Fiscal 2025 totaled $98.6 million, with adjusted diluted earnings per share at $1.81[30] - The company reported net earnings of $92.7 million for Fiscal 2025, with a diluted earnings per share of $1.70[30] Sales Growth - Organic sales growth was 2%, with a 1% increase in the Industrial Tool & Service (IT&S) segment and a 27% increase in Cortland Biomedical[5] - Industrial Tools & Services segment experienced a year-over-year growth of 2%[26] - Other Enerpac Tool Group reported a significant year-over-year growth of 33%[26] - The Industrial Tools & Services Segment reported net sales of $286.448 million for the first half of fiscal year 2026, up from $280.850 million in the same period of fiscal year 2025[28] - Organic sales growth for the Industrial Tools & Services Segment was flat at 0% for the first half of fiscal year 2026, compared to a decline of 2% in the previous year[28] - The Industrial Tools & Services Product line generated $237.4 million in revenue, reflecting a 5% increase compared to the previous year[29] Cash Flow and Investments - Year-to-date operating cash flow increased to $29 million, up from $16 million in the prior year[8] - Cash provided by operating activities for the six months ended February 28, 2026, was $29.027 million, significantly higher than $16.108 million in 2025, an increase of 80.0%[25] - Cash used in investing activities for the six months ended February 28, 2026, was $(6.683) million, compared to $(38.713) million in 2025, indicating a reduction in cash outflow by 82.7%[25] - Cash used in financing activities for the six months ended February 28, 2026, was $(75.339) million, up from $(25.069) million in 2025, an increase of 200.0%[25] - Free cash flow for Fiscal 2026 is anticipated to be between $100 million and $110 million, based on cash provided by operating activities of $115 million to $120 million[33] Guidance and Projections - The company plans to narrow its full-year FY2026 guidance, projecting net sales between $635 million and $650 million[11] - Adjusted EPS guidance for FY2026 is set between $1.85 and $1.92[11] - For Fiscal 2026, the company projects GAAP operating profit between $141 million and $148 million, with adjusted EBITDA expected to range from $158 million to $163 million[33] - Management does not provide guidance on certain GAAP financial measures due to uncertainties in predicting potential impairments and other costs[34] Shareholder Actions - The company repurchased approximately 1.3 million shares for a total of $51 million in Q2 FY2026[9] - The weighted average diluted shares outstanding for the three months ended February 28, 2026, were 52,300, compared to 54,808 in the same period of 2025, a decrease of 4.6%[23] Expenses and Charges - Gross profit margin declined by 410 basis points year-over-year to 46.4% due to pressures in the service business[6] - Adjusted Selling, General and Administrative expenses totaled $42,318, a slight increase from $41,423[26] - The company incurred restructuring charges of $5.862 million in fiscal year 2026, compared to $3.283 million in fiscal year 2025[27] - Financing costs for the fiscal year 2026 totaled $9.911 million, an increase from $2.265 million in the previous year[27] - M&A charges amounted to $(152), a decrease from $(258) in the prior year[26] - M&A charges totaled $1.4 million for Fiscal 2025, with additional charges expected in the upcoming fiscal year[30]